Skip to main content

Royalty Pharma Plc Cl A(RPRX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low45.04
Day High46.06
Open:45.94
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

Top Stories: Royalty Pharma Plc Cl A

Select a category then submit the form to load news
GlobeNewswire
Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence
GlobeNewswire
Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform
GlobeNewswire
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing
GlobeNewswire
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
GlobeNewswire
Royalty Pharma to Present at TD Cowen’s 46th Annual Health Care Conference
StockStory
3 Healthcare Stocks Walking a Fine Line
MTD
StockStory
5 Insightful Analyst Questions From Royalty Pharma’s Q4 Earnings Call
RPRX
Tipranks
Royalty Pharma Earnings Call Balances Strength And Risk
Motley Fool
Patient Capital Bet Heavily on Chime Financial (CHYM) With a 2.04 Million Share Purchase
Tipranks
Analysts Conflicted on These Healthcare Names: Dexcom (DXCM), Vertex Pharmaceuticals (VRTX) and Royalty Pharma (RPRX)
Tipranks
Bank of America Securities Keeps Their Buy Rating on Royalty Pharma (RPRX)
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (INCY), Edwards Lifesciences (EW) and Royalty Pharma (RPRX)
Motley Fool
Royalty Pharma (RPRX) Q4 2025 Earnings Transcript
StockStory
Royalty Pharma (NASDAQ:RPRX) Reports Sales Below Analyst Estimates In Q4 CY2025 Earnings
RPRX
GlobeNewswire
Royalty Pharma Reports Q4 and Full Year 2025 Results
StockStory
What To Expect From Royalty Pharma’s (RPRX) Q4 Earnings
RPRX
StockStory
3 Mid-Cap Stocks We Keep Off Our Radar
RPRX
StockStory
3 Profitable Stocks with Open Questions
HZO
GlobeNewswire
Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
GlobeNewswire
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire
Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
GlobeNewswire
Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
GlobeNewswire
Royalty Pharma Announces Dividend Increase
Tipranks
Citi Sticks to Their Buy Rating for Royalty Pharma (RPRX)
StockStory
Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Royalty Pharma (NASDAQ:RPRX)
RPRX
StockStory
3 Overrated Stocks We Steer Clear Of
LASR
GlobeNewswire
Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones
Tipranks
Royalty Pharma Announces Planned Legal Leadership Transition
Tipranks
Royalty Pharma Gains From FDA Approval of MYQORZO
StockStory
3 Healthcare Stocks We’re Skeptical Of
PGNY
GlobeNewswire
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million
Newswire.ca
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance

Profile

Royalty Pharma plc is a funder of biopharmaceutical industry. The compnay's portfolio includes royalties on commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta and Vertex's Kalydeco, Symdeko and Trikafta, and development-stage product candidates. Royalty Pharma plc is based in NEW YORK.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.